Panagora Asset Management’s Crescent Biopharma CBIO Stock Holding History

Panagora Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-651	Closed	-$196K	–	2843
2021 Q1	$196K	Sell	651 -411	-39%	-$147K	﹤0.01%	1727
2020 Q4	$399K	Sell	1,062 -727	-41%	-$255K	﹤0.01%	1315
2020 Q3	$549K	Sell	1,789 -2	-0.1%	-$764	﹤0.01%	1126
2020 Q2	$673K	Sell	1,791 -172	-9%	-$48.7K	﹤0.01%	1085
2020 Q1	$447K	Buy	1,963 +780	+66%	+$298K	﹤0.01%	1170
2019 Q4	$626K	Buy	+1,183	New	+$640K	﹤0.01%	1225
2016 Q3	–	Sell	-81	Closed	-$59K	–	2431
2016 Q2	$59K	Buy	+81	New	+$55.8K	﹤0.01%	2028
2014 Q2	–	Sell	-647	Closed	-$1.06M	–	2346
2014 Q1	$1.06M	Buy	+647	New	+$783K	0.01%	1156

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Panagora Asset Management's CBIO Position: Q2 2021 in Review

Panagora Asset Management sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 651 shares — an estimated $196K sold.

Panagora Asset Management first reported a position in CBIO in Q1 2014 and held it in 8 quarters. The position peaked at $1.06M in Q1 2014. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

Panagora Asset Management reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
Panagora Asset Management sold 651 Crescent Biopharma shares in Q2 2021, an estimated $196K.
Panagora Asset Management first reported a position in Crescent Biopharma in Q1 2014 and held it in 8 quarters.
Panagora Asset Management's Crescent Biopharma position peaked at $1.06M in Q1 2014.
58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on Panagora Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.